Product Information Requests Sample Clauses

Product Information Requests. Information concerning any complaints, inquiries and/or drug information requests from consumers, physicians, or other third parties regarding the Product shall be forwarded to DEPOMED within twenty-four (24) hours of MOVA’s receipt of the information and/or inquiry. DEPOMED shall respond to such complaints and inquiries, if necessary, in accordance with its usual and customary procedures. DEPOMED shall supply MOVA, for MOVA’s information purposes only, with copies of its standard response information for the Product as well as any updates thereto.
Sample 1Sample 2Sample 3See All (4)
AutoNDA by SimpleDocs
Product Information Requests. Information concerning any complaints, medical inquiries and/or drug information requests from consumers, physicians or other Third Parties *** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. received by Triangle regarding a Product in the Territory shall be forwarded to Xxxxxx'x Pharmacovigilence Department within *** of Triangle's receipt of the request. Xxxxxx'x Pharmacovigilence Department shall respond to such complaints, inquiries and requests, if necessary, in accordance with such Department's usual and customary procedures. Abbott shall supply Triangle, for Triangle's information purposes only, with copies of its standard response information for the Products as well as any updates thereto.
Sample 1Sample 2
Product Information Requests. Information concerning any complaints, inquiries and/or information requests from consumers, clinicians, or other third parties regarding the Product shall be forwarded to BioHorizons within [***] ([***]) [***] of Manufacturer’ receipt of the information and/or inquiry. BioHorizons shall respond to such complaints and inquiries, if necessary, in accordance with its usual and customary procedures.
Sample 1
Product Information Requests. Information concerning any complaints, inquiries and/or information requests from consumers, physicians, or other third parties regarding the Product shall be forwarded to NuVasive within three (3) business days of Pearsalls’ receipt of the information and/or inquiry. NuVasive shall respond to such complaints and inquiries, if necessary, in accordance with its usual and customary procedures. NuVasive shall supply Pearsalls, for Pearsalls’ information purposes only, with copies of its standard response information for the Products as well as any updates thereto.
Sample 1
Product Information Requests. Information concerning any complaints, inquiries, and/or drug information requests from consumers, physicians, or other third parties regarding the Product shall be communicated in writing to Depomed within twenty-four (24) hours of Patheon’s receipt of the information and/or inquiry. Depomed shall respond to such complaints and inquiries, if necessary, in accordance with its usual and customary procedures. Confidential Information, indicated by [***] has been omitted from this filing and filed separately with the Securities and Exchange Commission.
Sample 1
Product Information Requests. Information received by Sirtex concerning any complaints, inquiries and/or drug information requests from consumers, HCPs, or other third parties regarding the Product shall be forwarded to OncoSec within two (2) business days of Sirtex’s receipt of such information and/or inquiry. OncoSec shall be responsible for responding to all complaints and inquiries, if necessary, in accordance with its usual and customary procedures. OncoSec shall supply Sirtex, for its information purposes only, with copies of OncoSec’s active standard response information for the Product, and with any updates thereto, also for Sirtex’s information purposes only.
Sample 1
Product Information Requests. Information concerning any complaints, medical inquiries and/or drug information requests from consumers, physicians or other Third Parties received by a Party regarding a Product shall be forwarded to the Drug Information Department of the Party which is the holder of the ANDA for such Product within twenty-four (24) hours of such Party's receipt of the request. The Drug Information Department of the holder of the ANDA for such Product shall respond to such complaints, inquiries and requests, if necessary, in accordance with such Department's usual and customary procedures. The holder of the ANDA for a Product shall supply the other Party, for such Party's information only, with copies of its standard response information for the Products as well as any updates thereto. Any patient inquires or requests received by a Party shall be forwarded to the holder of the ANDA with respect to the Product related to such request.
Sample 1
AutoNDA by SimpleDocs
Product Information Requests. Information concerning any complaints, inquiries and/or drug information requests from consumers, physicians, or other third parties regarding the Product shall be forwarded to the Xxxxxx Medical Affairs Department within twenty-four (24) hours of Cephalon's receipt of the information and/or inquiry. The Xxxxxx Medical Affairs Department shall respond to such complaints and inquiries, if necessary, in accordance with its usual and customary procedures. Xxxxxx shall supply Cephalon, for Cephalon's information purposes only, with copies of its standard response information for the Product as well as any updates thereto.
Sample 1
Product Information Requests. At the request of HPG or a Purchaser, Vendor shall provide information on Products related to the following subjects: • Latex free • Mercury free • Polyvinyl Chloride (PVC) free • Di-ethylhexyl phthalate (DEHP) free • Certified by Green Seal or Environmental Choice Program • Compliance with U.S. Government’s Comprehensive Procurement Guidelines for recycled content (Product) • Compliance with U.S. Government’s Comprehensive Procurement Guidelines for recycled content (Packaging) • Energy Star Qualified • Halogenated organics free • Persistent Bioaccumulative Toxin (PBTs) free • Carcinogens and reproductive toxin free (CA Prop 65) • Full disclosure on product insert of all Product ingredients Ordering Process: EDI Purchase Order Verbal Facsimile
Sample 1

Related to Product Information Requests

  • Information Requests The parties hereto shall provide any information reasonably requested by the Servicer, the Issuer, the Seller or any of their Affiliates, in order to comply with or obtain more favorable treatment under any current or future law, rule, regulation, accounting rule or principle.

  • Information Request (a) The Owner Trustee shall provide any information regarding the Issuer in its possession reasonably requested in writing by the Servicer, the Administrator, the Seller or any of their Affiliates, in order to comply with or obtain more favorable treatment under any current or future law, rule, regulation, accounting rule or principle.

  • Product Information EPIZYME recognizes that by reason of, inter alia, EISAI’s status as an exclusive licensee in the EISAI Territory under this Agreement, EISAI has an interest in EPIZYME’s retention in confidence of certain information of EPIZYME. Accordingly, until the end of all Royalty Term(s) in the EISAI Territory, EPIZYME shall keep confidential, and not publish or otherwise disclose, and not use for any purpose other than to fulfill EPIZYME’s obligations, or exercise EPIZYME’s rights, hereunder any EPIZYME Know-How Controlled by EPIZYME or EPIZYME Collaboration Know-How, in each case that are primarily applicable to EZH2 or EZH2 Compounds (the “Product Information”), except to the extent (a) the Product Information is in the public domain through no fault of EPIZYME, (b) such disclosure or use is expressly permitted under Section 9.3, or (c) such disclosure or use is otherwise expressly permitted by the terms and conditions of this Agreement. For purposes of Section 9.3, each Party shall be deemed to be both the Disclosing Party and the Receiving Party with respect to Product Information. For clarification, the disclosure by EPIZYME to EISAI of Product Information shall not cause such Product Information to cease to be subject to the provisions of this Section 9.2 with respect to the use and disclosure of such Confidential Information by EPIZYME. In the event this Agreement is terminated pursuant to Article 12, this Section 9.2 shall have no continuing force or effect, but the Product Information, to the extent disclosed by EPIZYME to EISAI hereunder, shall continue to be Confidential Information of EPIZYME, subject to the terms of Sections 9.1 and 9.3 for purposes of the surviving provisions of this Agreement. Each Party shall be responsible for compliance by its Affiliates, and its and its Affiliates’ respective officers, directors, employees and agents, with the provisions of Section 9.1 and this Section 9.2.

  • Submission and Contents of Competitive Bid Quotes (a) Except as otherwise provided in Section 2.3.10, each Revolving Credit Lender may, in its sole discretion, submit a Competitive Bid Quote containing an offer or offers to make Competitive Bid Loans in response to any Invitation for Competitive Bid Quotes. Each Competitive Bid Quote must comply with the requirements of this Section 2.3.4 and must be submitted to the Competitive Bid Agent by telecopy at its offices specified in or pursuant to Article XIV not later than (i) 10:00 a.m. (New York time) at least three Business Days prior to the proposed Borrowing Date, in the case of a Eurodollar Auction or (ii) 10:00 a.m. (New York time) on the proposed Borrowing Date, in the case of an Absolute Rate Auction (or, in either case upon reasonable prior notice to the Revolving Credit Lenders, such other time and date as the Borrower and the Administrative Agent may agree); provided that, if the Administrative Agent is the Competitive Bid Agent, Competitive Bid Quotes submitted by the Administrative Agent as a Lender may only be submitted if the Administrative Agent notifies the Borrower of the terms of the offer or offers contained therein not later than 30 minutes prior to the latest time at which the relevant Competitive Bid Quotes must be submitted by the other Revolving Credit Lenders. Subject to Articles V and IX, any Competitive Bid Quote so made shall be irrevocable except with the written consent of the Competitive Bid Agent given on the instructions of the Borrower (if the Borrower is not the Competitive Bid Agent).

  • Compliance with Information Requests Notwithstanding any other provision of the Deposit Agreement or any ADR(s), each Holder and Beneficial Owner agrees to comply with requests from the Company pursuant to applicable law, the rules and requirements of any stock exchange on which the Shares or ADSs are, or will be, registered, traded or listed or the Articles of Association of the Company, which are made to provide information, inter alia, as to the capacity in which such Holder or Beneficial Owner owns ADSs (and Shares as the case may be) and regarding the identity of any other person(s) interested in such ADSs and the nature of such interest and various other matters, whether or not they are Holders and/or Beneficial Owners at the time of such request. The Depositary agrees to use its reasonable efforts to forward, upon the request of the Company and at the Company’s expense, any such request from the Company to the Holders and to forward to the Company any such responses to such requests received by the Depositary.

  • KYC Information (i) Upon the reasonable request of any Lender made at least five (5) days prior to the Closing Date, the Borrowers shall have provided to such Lender, and such Lender shall be reasonably satisfied with, the documentation and other information so requested in connection with applicable “know your customer” and anti-money-laundering rules and regulations, including, without limitation, the PATRIOT Act, in each case at least five (5) days prior to the Closing Date.

  • Information in Interest Election Requests Each telephonic and written Interest Election Request shall specify the following information in compliance with Section 2.02:

  • Client Information (2) Protected Health Information in any form including without limitation, Electronic Protected Health Information or Unsecured Protected Health Information (herein “PHI”);

  • Electronic Information Each Member hereby agrees that all current and future notices, confirmations and other communications may be made by the Company via email, sent to the email address of record of the Member provided to the Company as changed or updated from time to time, without necessity of confirmation of receipt, delivery or reading, and such form of electronic communication is sufficient for all matters regarding the relationship between the Company and the Members except as otherwise required by law. If any such electronically sent communication fails to be received for any reason, including but not limited to such communications being diverted to the recipients spam filters by the recipients email service provider, or due to a recipient’s change of address, or due to technology issues by the recipients service provider, the parties agree that the burden of such failure to receive is on the recipient and not the sender, and that the sender is under no obligation to resend communications via any other means, including but not limited to postal service or overnight courier, and that such communications shall for all purposes, including legal and regulatory, be deemed to have been delivered and received. Except as required by law, no physical, paper documents will be sent to Members, and a Member desires physical documents then such Member agrees to be satisfied by directly and personally printing, at such Member’s own expense, the electronically sent communication(s) and maintaining such physical records in any manner or form that a Member desires.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!